Correction of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction
https://doi.org/10.20996/1819-6446-2025-3121
Abstract
Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism.
Material and methods. An uncontrolled study included 30 patients with CHFpEF NYHA class I-III and anaemia. Patients received "standard therapy" for CHF in combination with sucrosomial iron (60 mg/day orally) for three months. Treatment response was assessed via clinical blood test, iron metabolism parameters, inflammatory markers, and functional tests at baseline and three months post-treatment.
Results. Anaemia in CHFpEF corresponds to anaemia of chronic disease with elevated hepcidin content, 219 (149-553) ng/mL occurs with impaired absorption and metabolism of iron and the development of iron deficiency. Hemoglobin levelincreased from 115 (98-117) g/L to 120 (103-133) g/L, p = 0.01, red blood cell count increased from 3.6 (3.5-4.1) × 1012/L to 4 (3.7-5.3) × 1012/L, p = 0.05, and serum ferritin increased from 106 (40-181) μg/L to 117 (83-166) μg/L, p = 0.04. N-terminal natriuretic propeptide (NT-proBNP) level decreased from 374 (330-443) ng/mL to 236 (128-349) ng/mL, p = 0.004. After treatment, exercise tolerance exercise tolerance improved: 6-minute walk test distance increased from 343.1 ± 100 m to 397±73 m (p = 0.01). Quality of life (QoL) level increased and was determined by the clinical status assessment scale (CAS), p = 0.01 and by the Minnesota Health Failure Questionnaire (MHFLQ), p = 0.002.
Conclusion. Adding oral hepcidin- independent iron to standard HFpEF therapy in patients with CHFpEF and anaemia significantly increased hemoglobin and serum ferritin levels, exercise tolerance, and QoL scores while reducing NT-proBNP levels and NYHA functional class after three months.
Keywords
chronic heart failure,
preserved left ventricular ejection fraction,
anaemia,
iron deficiency,
sucrosomial iron,
functional adaptation
Supporting agencies: None
About the Authors
A. A. Gurkina
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Anna A. Gurkina
Moscow
N. I. Stuklov
Peoples’ Friendship University of Russia named after Patrice Lumumba; National Medical Research Radiological Center
Russian Federation
Russian Federation
Nikolai I. Stuklov
Moscow
V. A. Kokorin
Peoples’ Friendship University of Russia named after Patrice Lumumba; N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Valentin A. Kokorin
Moscow
R. R. Gimadiev
Peoples’ Friendship University of Russia named after Patrice Lumumba; Eurotest LLC
Russian Federation
Russian Federation
Rinat R. Gimadiev
Moscow
N. V. Varekha
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
Nikolai V. Varekha
Moscow
References
1. Larina VN, Bart BY, Larin VG. Clinical significance of anemic syndrome in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2010;6(3):311-7 (In Russ.) DOI: 10.20996/1819-6446-2010-6-3-311-317.
2. Larina VN. Anemia in the practice of a general practitioner: a new look at an old problem. RMJ. 2019;27(12):44-50 (In Russ.)
3. Vatutin NT, Taradin GG, Kanisheva IV, Venzheha VV. Anemia and iron deficiency in patients with chronic heart failure. Kardiologiia. 2019;59(4S):4-20 (In Russ.) DOI: 10.18087/cardio.2638.
4. Zykov MV, Kashtalap VV, Bykova IS, et al. Comorbidity in myocardial infarction complicated by acute heart failure. Russian Journal of Cardiology. 2020;25(7):3427 (In Russ.) DOI: 10.15829/1560-4071-2020-3427.
5. Ponikowski P, Voors AA, Anker SD, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI: 10.1093/eurheartj/ehw128.
6. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342-433. DOI: 10.1016/j.cjca.2017.08.022.
7. Cohen- Solal A, Damy T, Terbah M, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16(9):984-91. DOI:10.1002/ejhf.139.
8. Núñez J, Domínguez E, Ramón JM, et al. Iron deficiency and functional capacity in patients with advanced heart failure with preserved ejection fraction. Int J Cardiol. 2016;207:365-7. DOI: 10.1016/j.ijcard.2016.01.187.
9. Stuklov NI. Iron deficiency and anemia in patients with chronic heart failure. Rational Pharmacotherapy in Cardiology. 2017;13(5):651-60 (In Russ.) DOI: 10.20996/1819-6446-2017-13-5-651-660.
10. Silverberg DS, Wexler D, Schwartz D. Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure? Int J Mol Sci. 2015;16(6):14056-74. DOI: 10.3390/ijms160614056.
11. Niehaus ED, Malhotra R, Cocca- Spofford D, et al. Repletion of Iron Stores with the Use of Oral Iron Supplementation in Patients with Systolic Heart Failure. J Card Fail. 2015;21(8):694–7. DOI: 10.1016/j.cardfail.2015.05.006.
12. Melnik MV, Shilov AM, Kim IR, et al. Chronic heart failure and iron deficiency anemia. Rational Pharmacotherapy in Cardiology. 2007;3(1):9-14 (In Russ.) DOI: 10.20996/1819-6446-2007-3-1-9-14.
13. Galyavich AS, Tereshchenko SN, Uskach TM, et al. Chronic heart failure. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(11):6162 (In Russ.) DOI: 10.15829/1560-4071-2024-6162.
14. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. DOI: 10.1093/eurheartj/ehad195.
15. Karavidas A, Troganis E, Lazaros G, et al. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail. 2021;23(4):593-7. DOI:10.1002/ejhf.2092.
16. Fabiano A, Brilli E, Mattii L, et al. Ex Vivo and in Vivo Study of Sucrosomial Iron Intestinal Absorption and Bioavailability. Int J Mol Sci. 2018;19(9):2722. DOI: 10.3390/ijms19092722.
17. Baranov II, Salnikova IA, Nesterova LA. Clinical guidelines for the diagnosis and treatment of iron deficiency conditions: a view from 2022. Obstetrics and Gynecology: news, opinions, training. 2022;10(2):56-64 (In Russ.) DOI: 10.33029/2303-9698-2022-10-2-56-64.
18. Smirnova MP, Chizhov PA, Baranov AA, Rechkina OP. Inflammatory markers interleukin-6, C-reactive protein and hepcidin in patients with chronic heart failure and iron deficiency. Vyatka Medical Bulletin. 2022;2(74):47-53 (In Russ.) DOI: 10.24412/2220-7880-2022-2-47-53.
19. Levina AA, Kazyukova TV, Tsvetaeva NV, et al. Hepcidin as a regulator of iron homeostasis. Pediatrics. Journal im. G. N. Speransky. 2008;87(1):67-74 (In Russ.)
20. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005;105(10):4103-5. DOI: 10.1182/blood-2004-12-4844.
Review
For citations:
Gurkina A.A., Stuklov N.I., Kokorin V.A., Gimadiev R.R., Varekha N.V. Correction of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction. Rational Pharmacotherapy in Cardiology. 2025;21(1):33-38. (In Russ.) https://doi.org/10.20996/1819-6446-2025-3121
Views:
316
Email this article 